VectorY
VectorY develops gene therapies combining antibodies and gene therapy, focusing on CNS and muscle disorders. The Amsterdam-based biotech raised $176M in Series A funding in November 2023 and employs 112 people.
The growth story
VectorY grew from 23 to 112 employees between 2021 and 2026, raising $176M along the way, most recently a Series A in November 2023.
About
VectorY creates gene therapies that use antibodies to treat central nervous system and muscle disorders. Its therapies aim to provide long-lasting treatments for diseases with high unmet medical needs. The company operates its own R&D and manufacturing facilities in Amsterdam.
The company raised $176M in Series A funding in November 2023, backed by major life science investors including EQT Life Sciences and Forbion Capital Partners. With 112 employees, VectorY has built a fully integrated gene therapy operation since its 2020 founding.
Founders and leadership
VectorY’s largest function is Research, with 19 employees. The company operates with a median tenure of 2 years, suggesting a relatively young organization. Its leadership team comes from major biotech and academic institutions.
The VectorY org chart
Jim Scibetta (Chief Executive Officer) leads 24 mapped leaders with 6 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 23 (+35% YoY), Engineering 17 (+31% YoY), Operations 13 (+8% YoY), Business Development 13 (+30% YoY), Information Technology 7 (+17% YoY), Administrative 5 (+67% YoY).
Talent flow
VectorY recruits heavily from uniQure, Amsterdam UMC, and Johnson & Johnson Innovative Medicine. Alumni frequently move to academic medical centers like UMC Utrecht and Leiden University Medical Center. The company’s workforce is educated primarily at Dutch universities, with Wageningen University & Research being the top feeder school.
Most common previous employers of VectorY staff: uniQure (12), Amsterdam UMC (8), Johnson & Johnson Innovative Medicine (7), Utrecht University (5), UMC Utrecht (5), Galapagos (5). Former VectorY employees most often moved to UMC Utrecht (5), Forbion (3), ProQR Therapeutics (2), KU Leuven (2), Leiden University Medical Center (2), Applied Biopharm Consulting (1).
Alumni worth knowing
The VectorY mafia
VectorY alumni have founded three companies, including Neurogen Biomarking and Applied Biopharm Consulting. These startups focus on biomarkers and biopharmaceutical consulting, respectively.
3Elisabeth Thijssen, PhD, was Manager of Business Development until 2024Anthony Newcombe, was Co-founder & Chief Operating Officer until 2023Thomas Gundelund Rasmussen, was Head of Business Development until 2023Web traffic
Traffic mix: 45% direct, 32% search, 15% social, 1% paid.
What this company is made of
Most common skills at VectorY: Molecular Biology (41), Cell Culture (32), Project Management (30), Polymerase Chain Reaction (PCR) (29), Life Sciences (28), Research Skills (28), Biotechnology (27), Microsoft Office (24).
Where the team actually sits
VectorY people are concentrated in North Holland, Netherlands (25), Netherlands (16), Utrecht, Netherlands (12), South Holland, Netherlands (8).
Search footprint
VectorY attracts about 151 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 12 ranking keywords and lost 10 in the last period.
What employees say
- Compensation
- 4.00 / 5
- Career opportunities
- 3.70 / 5
- Senior management
- 4.30 / 5
- Work-life balance
- 3.70 / 5
Frequently asked
VectorY has 112 employees as of September 2026.
VectorY has raised $176M in total, most recently a Series A round in November 2023.
Jim Scibetta (Chief Executive Officer) sits at the top of VectorY's reporting structure, with 6 direct reports.
The most common previous employers of current VectorY staff are uniQure (12 people), Amsterdam UMC (8 people), Johnson & Johnson Innovative Medicine (7 people).
Former VectorY employees most often move to UMC Utrecht (5), Forbion (3), ProQR Therapeutics (2).
At least 3 companies have a founder who previously worked at VectorY, including Neurogen Biomarking, Applied Biopharm Consulting, de novo foundry.
VectorY attracts about 151 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among VectorY staff are Molecular Biology, Cell Culture, Project Management, Polymerase Chain Reaction (PCR), Life Sciences.
VectorY staff are concentrated in North Holland, Netherlands (25), Netherlands (16), Utrecht, Netherlands (12).
VectorY has about 23 people in Research, up 35% over the past year, as of September 2026.
VectorY has about 17 people in Engineering, up 31% over the past year, as of September 2026.
Computed from 81 current and 71 former VectorY profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.